Lilly's donanemab data prompted Califf to discuss the dawning of a new era in Alzheimer's treatments. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
